8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Summit Therapeutics Inc. (SMMT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 36,391,063 | $689,974,554 | 3.96% | |
| 2. | D E Shaw D. E. Shaw | 2,242,229 | $42,512,661 | +440% | 0.03% |
| 3. | Superstring Capital Management Ting Guo | 892,873 | $16,928,872 | 12.09% | |
| 4. | Point72 Asset Management Steve Cohen | 784,186 | $14,868,167 | 0.02% | |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 710,000 | $13,461,600 | 0.79% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.74 | 533,617 | $9,999,982.58 | 32,057,147 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.07 | 5,000 | $90,350.00 | 556,093,090 | 2025-09-11 | Filing | |
| $17.68 | 333,394 | $5,894,405.92 | 556,088,090 | 2025-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,853,199 | $205,776,661 | 0.01% | |
| 2. | 9,653,758 | $183,035,250 | 0% | |
| 3. | 7,028,160 | $133,253,914 | 0% | |
| 4. | 5,711,802 | $108,295,766 | 0% | |
| 5. | 5,233,252 | $99,222,458 | 0% |
News See All
10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts
The equity market remains bullish, driven by a record-setting trend fueled by renewed enthusiasm for artificial intelligence.
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates
Summit Therapeutics climbed by 15.44 percent on Wednesday to close at $17.94 apiece, as investors repositioned portfolios ahead of updates on a clinical trial for its lung cancer treatment candidate, ...
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More
The company said that it has begun recruiting highly-skilled German talent to operationalize its upcoming satellite manufacturing facility in Berlin, as part of its plan to double the production capacity...
15 Large Cap Stocks Under $30 With Huge Upside Potential
On March 20, Caroline Woods from The Street sat down with Mo Haghbin, Managing Director at ProShares, to break down where the money is actually going amid a market dealing with rising geopolitical tensions...
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks with explosive growth potential.
10 Stocks With Explosive Growth Potential
On February 26, Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, appeared on BNN Bloomberg to share his outlook on Global and Technology Stocks.
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc.
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Summit Therapeutics Q4 and Year-End 2025 Earnings Call. [Operator Instructions] We do not expect any technical difficulties today.
Hedge Fund Resource Center